Cargando…

Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers

The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) has been tasked by the World Health Organization (WHO) to review the extent to which animal-based testing methods are described in their manuals, guidelines and recommendations for vaccines and bioth...

Descripción completa

Detalles Bibliográficos
Autores principales: Lilley, Elliot, Coppens, Emmanuelle, Das, Pradip, Galaway, Francis, Isbrucker, Richard, Sheridan, Sarah, Stickings, Paul, Holmes, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109345/
https://www.ncbi.nlm.nih.gov/pubmed/36376163
http://dx.doi.org/10.1016/j.biologicals.2022.11.002
_version_ 1785027044747247616
author Lilley, Elliot
Coppens, Emmanuelle
Das, Pradip
Galaway, Francis
Isbrucker, Richard
Sheridan, Sarah
Stickings, Paul
Holmes, Anthony
author_facet Lilley, Elliot
Coppens, Emmanuelle
Das, Pradip
Galaway, Francis
Isbrucker, Richard
Sheridan, Sarah
Stickings, Paul
Holmes, Anthony
author_sort Lilley, Elliot
collection PubMed
description The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) has been tasked by the World Health Organization (WHO) to review the extent to which animal-based testing methods are described in their manuals, guidelines and recommendations for vaccines and biotherapeutics. The aim is to identify and recommend where updates to these documents can lead to an increased and more harmonised adoption of 3Rs principles (i.e. Replacement, Reduction and Refinement of animal tests) in the quality control and batch release testing requirements for vaccines and biotherapeutics. Developing recommendations that are widely applicable by both the manufacturers and national regulatory authorities for vaccines and biologicals globally requires a detailed understanding of how different organisations view the opportunities and barriers to better integration of the 3Rs. To facilitate this, we developed and distributed a survey aimed at vaccine and biotherapeutics manufacturers in July 2021. In this paper, we present the key findings from this survey and how these will help inform the recommendations for wider integration of 3Rs approaches by WHO in their guidance documents applicable to the quality control and batch testing of vaccines and biotherapeutics.
format Online
Article
Text
id pubmed-10109345
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Academic Press
record_format MEDLINE/PubMed
spelling pubmed-101093452023-04-18 Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers Lilley, Elliot Coppens, Emmanuelle Das, Pradip Galaway, Francis Isbrucker, Richard Sheridan, Sarah Stickings, Paul Holmes, Anthony Biologicals Article The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) has been tasked by the World Health Organization (WHO) to review the extent to which animal-based testing methods are described in their manuals, guidelines and recommendations for vaccines and biotherapeutics. The aim is to identify and recommend where updates to these documents can lead to an increased and more harmonised adoption of 3Rs principles (i.e. Replacement, Reduction and Refinement of animal tests) in the quality control and batch release testing requirements for vaccines and biotherapeutics. Developing recommendations that are widely applicable by both the manufacturers and national regulatory authorities for vaccines and biologicals globally requires a detailed understanding of how different organisations view the opportunities and barriers to better integration of the 3Rs. To facilitate this, we developed and distributed a survey aimed at vaccine and biotherapeutics manufacturers in July 2021. In this paper, we present the key findings from this survey and how these will help inform the recommendations for wider integration of 3Rs approaches by WHO in their guidance documents applicable to the quality control and batch testing of vaccines and biotherapeutics. Academic Press 2023-02 /pmc/articles/PMC10109345/ /pubmed/36376163 http://dx.doi.org/10.1016/j.biologicals.2022.11.002 Text en . https://creativecommons.org/licenses/by/3.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Lilley, Elliot
Coppens, Emmanuelle
Das, Pradip
Galaway, Francis
Isbrucker, Richard
Sheridan, Sarah
Stickings, Paul
Holmes, Anthony
Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers
title Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers
title_full Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers
title_fullStr Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers
title_full_unstemmed Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers
title_short Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers
title_sort integrating 3rs approaches in who guidelines for the batch release testing of biologicals: responses from a survey of vaccines and biological therapeutics manufacturers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109345/
https://www.ncbi.nlm.nih.gov/pubmed/36376163
http://dx.doi.org/10.1016/j.biologicals.2022.11.002
work_keys_str_mv AT lilleyelliot integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers
AT coppensemmanuelle integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers
AT daspradip integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers
AT galawayfrancis integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers
AT isbruckerrichard integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers
AT sheridansarah integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers
AT stickingspaul integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers
AT holmesanthony integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers